Intervention Prioritisation

In Trial

• Simvaststain
  First reviewed: April 01 2023

  Simvastatin competitively inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, an enzyme involved in cholesterol synthesis.

• Baricitinib
  First reviewed: April 01 2023

  Baricitinib selectively and reversibly inhibits the Janus-associated tyrosine kinases JAK1 and JAK2.

Prioritised

• Atibuclimab
  First reviewed: April 01 2023

  Atibuclimab (IC14) is a chimeric CD14 antibody

• Complement inhibitors
  First reviewed: April 01 2023

  Specific drugs prioritised to date:

  • Vilobelimab (a human-mouse chimeric IgG4 kappa antibody that targets human C5a in plasma)
• IL-6 receptor inhibitors
  First reviewed: April 01 2023

  Specific drugs prioritised to date:

  • Tocilizumab
• TNF-alpha inhibitors
  First reviewed: April 01 2023

  Specific drugs prioritised to date:

  • Infliximab

Under review

• Artesunate
  First reviewed: August 01 2023

  Insufficient evidence at this time.

• CRAC channel inhibitors
  First reviewed: August 01 2023

  Insufficient evidence at this time.

  Specific drugs considered to date:

  • Auxora (CM4620)
• Furosemide
  First reviewed: April 01 2023

  nebulised/inhaled

  Insufficient evidence at this time.

• Galectin-3 inhibitors
  First reviewed: April 01 2023

  Insufficient evidence at this time.

  Specific drugs considered to date:

  • Belapectin (nebulised/inhaled)
• Macrolides
  First reviewed: April 01 2023

  Insufficient evidence at this time.

• p38 MAPK inhibitors
  First reviewed: April 01 2023

  Insufficient evidence at this time.

  Specific drugs considered to date:

  • Dilmapimod
• PSCK9 inhibitors
  First reviewed: August 01 2023

  Insufficient evidence at this time.

• Neutrophil elastase inhibitors
  First reviewed: August 01 2023

  Insufficient evidence at this time.

  Specific drugs considered to date:

  • Sivelestat
• Sphingosine 1-phosphate receptor modulators
  First reviewed: April 01 2023

  Insufficient evidence at this time.

  Specific drugs considered to date:

  • Fingolimod
• Tyrosine kinase inhibitors
  First reviewed: April 24 2023

  Insufficient evidence at this time.

  Specific drugs considered to date:

  • Imatinib.

Not-prioritised

• Aspirin
  First reviewed: April 24 2023

  Not prioritised on the basis of prevalence of use in the target population and poor recruitment in previous ARDS trials.

• Citrulline
  First reviewed: April 24 2023

  Not prioritised on the basis of insufficient evidence for efficacy and lack of biological plausibility.

• Corticosteroids
  First reviewed: April 24 2023

  Not prioritised on the basis of ongoing or proposed trials.

• N-acetyl-cysteine
  First reviewed: April 24 2023

  nebulised/inhaled

  Not prioritised on the basis of insufficient evidence for efficacy and lack of biological plausibility.

• Streptokinase
  First reviewed: April 24 2023

  nebulised/inhaled

  Not prioritised on the basis of insufficient evidence for efficacy and lack of biological plausibility.